Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?
CD4(+)/CD56(+) haematodermic neoplasm or 'early' plasmacytoid dendritic cell leukaemia/lymphoma (pDCL) was described as a disease entity in the last World Health Organisation/European Organisation for Research and Treatment of Cancer classification for cutaneous lymphomas. These leukaemia/lymphomas co-express CD4 and CD56 without any other lineage-specific markers and have been identified as arising from plasmacytoid dendritic cells. Despite a fairly homogeneous pattern of markers expressed by most pDCL, numerous distinctive features (e.g. cytological aspects and aberrant marker expression) have been reported. This may be related to the 'lineage-independent developmental' programme of dendritic cells, which may be able to develop from either immature or already committed haematopoietic progenitors. This highlights the need for specific validated markers to diagnose such aggressive leukaemia. Here, we propose--among others (e.g. T-cell leukaemia 1)--blood dendritic cell antigen-2 and high levels of CD123 expression as potential markers. In addition, we propose a multidisciplinary approach including several fields of haematology to improve pDCL diagnosis.
Garnache-Ottou
Francine
F
EFS BFC, Haematology and Immunology Laboratory, Besançon, France. francine.garnache@efs.sante.fr
Feuillard
Jean
J
Saas
Philippe
P
D014408:Biomarkers, Tumor / Q000032:analysis; D003713:Dendritic Cells / Q000276:immunology*; D003937:Diagnosis, Differential; D006410:Hematopoiesis; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000175:diagnosis* / Q000276:immunology
D014408:Biomarkers, Tumor